BBP News and Press, Virtus LifeSci Biotech Products From 12/13/21

Aeta: We know the transmissibility is higher for the omicron variant and will impact vaccine efficacy, but anecdotal hospital reports suggest that it milder. Aeta: Health care is having a solid year but is still lagging the market, as cyclicals are outperforming due to the strong econ...

While inflation was at first believed to be transitory, it is now beginning to look persistent. Biotech stocks are close to 6.5% of the Russell 2000 Value Index benchmark, and only a few have earnings and positive cash flows. We also think the outlook is rosy for small-cap value i...

With each new outbreak and variant, comes new fears, government lockdowns and hopes for recovery through science and medicine in the form of effective vaccines. Until recently, investor mindsets had shifted to a “living with COVID-19” mentality, supported by abundant sti...

The latest IHS Markit US Sector PMI revealed that six of the seven broad sectors tracked by the surveys reported higher output in November. Despite some of the supply chain problems having eased in November, the extent to which production growth had been constrained is consistent with...

The biotechnology sector largely underperformed the broader market this year, particularly small- to mid-cap biotech indexes whose constituents tend to experience more volatility. Contributing factors to the market decline include fears of increased regulation and oversight of M&A...

The revolutionary technology of synthetic biology is poised to make a profound impact on the way a vast array of products are manufactured, from lab-grown meat to cosmetics to biodegradable packaging. Like the internet revolution, companies that enable or effectively harness synthetic...

We are particularly enthused about a broad area that falls within the life science tools and services category, where we find many companies that are enabling innovative breakthroughs. Other growth themes in healthcare have either arisen or accelerated due to the COVID-19 pandemic. Th...

In making the case for less stringent regulations, pharmaceutical companies highlight the distinctions between list prices and net prices. The industry projects potential negative implications for patient access and R&D investments, and support in Congress has historically be limi...

The after-effects of pandemic-era policies will be with us for some time - with many supply chains and labor markets still experiencing significant disruption. Everyone likes to complain about drug prices, but here is the unpleasant truth: discovering new drugs is expensive and risky....

Taking a look at how the expected Q3 ’21 sector revenue growth rates have changed since mid-August ’21 or the unofficial end of Q2 ’21 earnings season. Per Bespoke’s research, the S&P 500 has now reached “extremely oversold” levels, worse ...